1-3 of 3
Eva M. Ciruelos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margeli Vila, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, Yuan Liu, Daniel Fernandez-Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C. Turner, Miguel Martín
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4166–4177.
https://doi.org/10.1158/1078-0432.CCR-23-0956
Published: 13 October 2023
View article titled, Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Open the PDF for Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, Rosa I. Gallagher, Cristina Saura, Paolo G. Nuciforo, Isabel Calvo, Jay Andersen, José Luis Passos-Coelho, Miguel J. Gil-Gil, Begoña Bermejo, Debra A. Pratt, Eva M. Ciruelos, Patricia Villagrasa, Matthew J. Wongchenko, Emanuel F. Petricoin, Mafalda Oliveira, Steven J. Isakoff
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 993–1003.
https://doi.org/10.1158/1078-0432.CCR-21-2498
Published: 01 March 2022
View article titled, Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Open the PDF for Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data